We are seeing patients in-person and through Video Visits. Learn more about how we’re keeping you safe and please review our updated visitor policy. Please also consider supporting Weill Cornell Medicine’s efforts to support our front-line workers.
Sandra and Edward Meyer Cancer Center

Warning message

The subscription service is currently unavailable. Please try again later.

You are here


Phase II Study of Additional Treatment in Patients With Non-Hodgkin Lymphoma Shows No Significant Benefit

Tuesday, September 19, 2017

A phase II trial reported in the Journal of Clinical Oncology by John P. Leonard, M.D., and collaborators showed no significant progression-free survival benefit of adding bortezomib to R-CHOP.